10-K: Bowhead Specialty Reports Strong Revenue Growth Amid Underwriting Profitability Decline

Bowhead Specialty Holdings Inc. announced a 24% increase in gross written premiums and a 40.6% rise in net income for 2025, despite a notable decrease in underwriting income and an uptick in its loss ratio.

Summary

• Gross written premiums increased by 24.0% to $862.8 million for the year ended December 31, 2025, up from $695.7 million in 2024.
• Net income rose by 40.6% to $53.8 million in 2025, compared to $38.2 million in 2024.
• Net investment income saw a significant increase of 44.1% to $57.8 million in 2025.
• The expense ratio improved by 1.6 points, decreasing to 29.8% in 2025 from 31.4% in 2024, driven by business scaling and prudent expense management.
• Underwriting income, a non-GAAP measure, decreased by 18.4% to $14.9 million in 2025 from $18.2 million in 2024.
• The loss ratio increased by 2.3 points to 66.7% in 2025 from 64.4% in 2024, primarily due to higher expected loss ratios in Professional Liability and Healthcare Liability and a portfolio mix shift towards Casualty.
• The combined ratio increased by 0.7 points to 96.5% in 2025, indicating a slight deterioration in overall underwriting profitability.
• Return on equity decreased by 0.5 points to 13.1% in 2025, and adjusted return on equity decreased by 1.6 points to 13.6%.
• The Baleen Specialty division experienced exceptional growth, with gross written premiums increasing by 1214.8% to $21.4 million in 2025.
• The company issued $150 million aggregate principal amount of 7.75% senior unsecured notes due December 1, 2030, generating net proceeds of $146.4 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While the company demonstrates impressive top-line growth and strong investment income, the decline in core underwriting profitability metrics like underwriting income, loss ratio, and combined ratio raises concerns about the sustainability of its core insurance operations. The increasing ceding fee to AmFam will also pressure future underwriting margins.

Positives

• Gross written premiums grew robustly by 24.0% to $862.8 million, demonstrating strong market penetration and demand for specialized insurance solutions.
• Net income increased significantly by 40.6% to $53.8 million, reflecting overall business expansion.
• Net investment income surged by 44.1% to $57.8 million, contributing substantially to total revenues.
• The expense ratio decreased by 1.6 points to 29.8%, indicating improved operational efficiency and scaling benefits.
• The Baleen Specialty division achieved remarkable growth of 1214.8% in gross written premiums, highlighting successful digital underwriting model expansion.
• The company maintains a strong balance sheet with no reserves from accident years prior to 2020, providing a clean slate for loss development.
• The investment portfolio is conservatively managed with an average credit rating of AA and 91.2% rated A or better, prioritizing capital preservation.
• All reinsurance business is placed with reinsurers rated A (Excellent) or better by A.M. Best, mitigating credit risk.
• The remote-friendly operating model is a competitive advantage for attracting and retaining top talent nationwide.
• The company operates on a new technology platform, unburdened by legacy systems, allowing for efficient operations and seamless integration of new tools.

Negatives

• Underwriting income decreased by 18.4% to $14.9 million, suggesting a decline in the core profitability of insurance operations.
• The loss ratio increased by 2.3 points to 66.7%, indicating higher claims costs relative to earned premiums.
• The combined ratio increased by 0.7 points to 96.5%, reflecting a reduction in underwriting profitability.
• Return on equity and adjusted return on equity both decreased, from 13.6% to 13.1% and 15.2% to 13.6% respectively.
• Net losses and loss adjustment expenses increased by 32.2%, outpacing the growth in net earned premiums.
• Net acquisition costs increased by 43.6%, also growing faster than net earned premiums, partly due to changes in portfolio mix and increasing ceding fees to AmFam.
• The ceding fee paid to AmFam on net premiums assumed will increase from 2.75% to 3.25% on May 23, 2026, and to 5.0% on May 23, 2027, which will further impact future underwriting profitability.
• The company relies on a select group of brokers, with 70.3% of gross written premiums in 2025 distributed through just four brokers, posing concentration risk.
• The Professional Liability division has experienced some softening of rates, particularly in risk management and public directors and officers lines.

Risks

• Inability to accurately assess underwriting risk, especially for complex E&S insurance, could lead to inappropriate premium rates or terms.
• Intense competition from domestic and international insurers, MGAs, and new market entrants, potentially reducing rates or negatively affecting terms.
• Inability to maintain the strategic relationship with American Family Mutual Insurance Company, S.I. (AmFam), which provides legal entities, ratings, and licenses.
• A decline in AmFam's financial strength rating or financial size category could adversely affect the company's ability to write new business.
• Exposure to risks arising from reliance on insurance retail agents, brokers, and wholesalers, including potential discontinuation of relationships or credit risk for unremitted premiums.
• Losses and loss expense reserves may be inadequate to cover actual losses, impacted by claims inflation, legislative activity, and litigation trends.
• Underwriting tools and algorithms, including proprietary BRATs, may not produce accurate predictions due to inherent uncertainties, inaccurate inputs, or unrepresented risks.
• Reliance on third-party data, where inaccuracies could adversely impact the ability to estimate losses and manage risks.
• Unexpected changes in the interpretation of coverage or policy provisions, including loss limitations and exclusions (e.g., war exclusions for cyber attacks), could broaden coverage or increase claim frequency/severity.
• Reinsurers may fail to reimburse claims on a timely basis or at all, due to insolvency, contractual disputes, or other reasons, despite the company's primary liability to policyholders.
• The insurance business is historically cyclical, and a shift from the current hard market could adversely affect financial performance.
• Adverse economic factors, such as recession or inflation, could reduce policy sales, increase claim frequency/severity, or lead to premium defaults.
• Trade relations between the United States and other countries, including tariffs, could adversely affect insureds, business, and financial results.
• Extensive state and federal regulation, including capital and surplus requirements, licensing, and changes of control, could limit business objectives or incur penalties.
• Potential for additional government or market regulation, including federal preemption of state AI insurance regulation, which could increase compliance costs.
• Changes in law, such as those relating to specific perils (e.g., defense within limits policies, extended statutes of limitations), could adversely affect pricing and claims.
• Anti-takeover provisions in organizational documents could delay or prevent a change of control.
• Loss of one or more key personnel, including the founder and CEO Stephen Sills, or inability to attract and retain qualified personnel.
• Security breaches, loss of data, cyberattacks, and other information technology failures could disrupt operations, damage reputation, and incur liabilities.
• Operational risk exposures, such as human or systems failures (including third-party vendors), could result in losses.
• The rapid evolution of AI and technology could alter the competitive landscape and introduce new vulnerabilities if not leveraged effectively.
• Management has the authority to change underwriting guidelines or strategy without stockholder approval.
• Inability to manage growth effectively, including meeting capital needs, expanding systems, and adhering to gross written premium restrictions in the AmFam Quota Share Agreement.
• Future acquisitions, strategic investments, or new platforms could expose the company to further risks or prove unsuccessful.
• Uncertain effects of litigation, including routine claims, class action lawsuits, and employment-related litigation (e.g., UK employment taxes).
• Loss of key vendor relationships or failure of a vendor to protect data could affect operations.
• Limited operating history may make it difficult to evaluate current business and future prospects.
• Potential need to sell investments at unfavorable prices to meet liquidity requirements if cash flows are insufficient.
• As a holding company, liquidity depends on dividends and distributions from subsidiaries, which are restricted by insurance laws.
• May require additional capital in the future, which may not be available or may only be available on unfavorable terms, potentially leading to dilution.
• Failure to comply with terms of the credit facility or senior notes indenture could result in an event of default and accelerate debt repayment.
• Current debt and ability to incur substantial indebtedness may reduce financial flexibility and divert cash flow for debt service.
• Restrictions in the Indenture and Credit Facility limit the ability to operate the business and pursue strategies.
• Increased costs and management time required for operating as a public company.
• Qualifying as an emerging growth company and utilizing reduced reporting requirements could make common stock less attractive to investors.
• GPC Fund and AFMIC exercise substantial influence over the company and may engage in competing businesses.
• No current plans to pay cash dividends on common stock, meaning investors may only realize returns through stock price appreciation.
• If securities or industry analysts do not publish research or publish inaccurate/unfavorable research, stock price and trading volume could decline.
• Substantial future sales of common stock by existing stockholders could cause the market price to decline.
• Delaware forum selection clause could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

The company aims to achieve its goals of growing its business and generating attractive returns for stockholders by attracting and retaining top talent, profitably growing existing lines, and opportunistically expanding into new products and markets. It plans to maintain an underwriting-first culture across market cycles and leverage technology, data, and analytics to drive performance. The ceding fee to AmFam is scheduled to increase to 3.25% on May 23, 2026, and to 5.0% on May 23, 2027. The 2025 Credit Facility matures on November 26, 2027, or earlier if MGA Agreements terminate without replacement. The company expects to put increasing reliance on its own loss data and claims practices for reserving over time.

Management Comments

• Our principal objective is to create and sustain superior returns for our stockholders by generating consistent, underwriting profits across our product offerings and through all market cycles, while prudently managing capital.
• We believe that our current market opportunity, differentiated expertise, relationships, culture and leadership team position us well to continue to grow our business profitably.
• We have established an underwriting-first culture, where from the top down, underwriting profitability is our North Star.
• Our goal as an organization is to build a technology stack that frees up our underwriters from performing highly repetitive, uniform tasks, which allows them to apply judgment, creativity and critical thinking to develop solutions that can be executed quickly.
• We believe that our employees value the flexibility of our operating model and appreciate knowing that we are not trying to change this model or require a full-time return to the office.
• We believe that investment decisions are best made when not excessively restrictive.
• We believe we have sufficient liquidity available at our holding company and subsidiaries to meet our operating cash needs and obligations for at least the next 12 months.

Industry Context

StockSavvy.ai notes that Bowhead Specialty operates in the highly competitive U.S. commercial Excess & Surplus (E&S) market, which was valued at $95.1 billion in 2024 and has grown 19.5% annually since 2019. The P&C industry is generally experiencing a 'hard market,' characterized by increased premium levels, though this cyclicality can be more pronounced in the E&S sector. While the company's Casualty division has benefited from these hard market conditions, its Professional Liability division has seen some rate softening. The rapid evolution of AI and technology, along with new regulatory guidance and executive orders concerning AI use in insurance, presents both opportunities and competitive risks for the industry.

Comparison to Industry Standards

• The company's gross written premium growth of 24.0% in 2025 outpaced the broader U.S. commercial E&S market's annual growth rate of 19.5% since 2019, indicating strong performance within its target segments.
• The P&C industry is generally experiencing a 'hard market,' which has more strongly affected the company's Casualty division, while its Healthcare Liability division is experiencing mixed conditions and its Professional Liability division has seen some softening of rates, particularly in risk management and public directors and officers lines, after a couple years of significant rate increases. This suggests varied alignment with broader market trends across its divisions.
• Due to its limited operating history, the company relies on industry data and benchmarks from actuarial consultants to supplement its own data for reserving parameters, which is a common practice for newer entrants but implies less reliance on proprietary experience compared to more established competitors like American International Group, Chubb Ltd., or W.R. Berkley Corporation.
• The company's combined ratio of 96.5% in 2025, while still profitable, increased from 95.8% in 2024. This indicates a slight deterioration in underwriting profitability compared to some industry leaders who consistently target combined ratios below 90% in favorable market conditions.

Corporate Governance

Legal Proceedings

• The company is subject to routine legal proceedings in the normal course of operating its insurance business, generally related to insurance and reinsurance claims, which are considered in the establishment of reserves.
• The company is not currently a party to any out-of-the-ordinary litigation that, if determined adversely, would have a material adverse effect on its business, results of operations, or financial condition.
• The company has accrued approximately $1.6 million as of December 31, 2025 (and $1.5 million as of December 31, 2024) for estimated employment taxes, penalties, and interest related to an employee domiciled in the United Kingdom since 2021.

Related Party Transactions

• American Family Mutual Insurance Company, S.I. (AmFam) beneficially owns approximately 14.3% of the company's issued and outstanding common stock as of December 31, 2025.
• The company leverages AmFam's legal entities, ratings, and licenses through Managing General Agency (MGA) Agreements and a Quota Share Agreement.
• Under the Quota Share Agreement, BICI assumes 100% of all Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty risks written on behalf of AmFam by BSUI.
• AmFam receives a ceding fee on net premiums assumed by BICI, which was 2.75% in 2025 and is scheduled to increase to 3.25% on May 23, 2026, and 5.0% on May 23, 2027.
• BICI is required to set aside assets in a trust to secure a portion of its reinsurance recoverable obligation under the AmFam Quota Share Agreement.
• Warrants were issued to AFMIC (an AmFam subsidiary) on May 22, 2024, and May 28, 2024, for the right to purchase a total of 1,670,721 shares of common stock at an exercise price of $17.00 per share, vesting 20% per year over five years. As of December 31, 2025, 334,144 warrants have vested, but none have been exercised.
• A separate subsidiary of AmFam participated in BICI's ceded quota share and excess of loss reinsurance treaties.
• For the year ended December 31, 2025, the company incurred $13.3 million in Ceding Fees under the AmFam Quota Share Agreement and ceded $34.7 million of written premiums to AmFam under reinsurance treaties.
• On August 6, 2025, Bowhead entered into a usage-based service agreement with Bold Penguin, an insurtech company owned by AmFam, incurring $0.1 million in operating expenses for the year.
• For the year ended December 31, 2025, BSUI bound $0.1 million of written premium with American Family Brokerage Inc., another subsidiary of AmFam.

Stakeholder Impact

• **Shareholders**: Experience strong revenue and net income growth, but face concerns regarding declining underwriting profitability and return on equity. Potential for dilution from future capital raises exists, and there are no current plans for cash dividends. The influence of GPC Fund and AmFam, along with anti-takeover provisions, may limit shareholder control.
• **Employees**: Benefit from a remote-friendly operating model, competitive benefits package, and opportunities for training and development. Key personnel are subject to non-compete and non-solicitation provisions.
• **Customers/Policyholders**: Receive specialized insurance solutions and quality service through tailored craft and digital underwriting models. Risks include potential for inaccurate underwriting and changes in coverage interpretation.
• **Brokers/Agents**: Maintain deep, long-term distribution relationships with the company, benefiting from timely responses and expertise. However, reliance on a select group of brokers creates concentration risk.
• **Creditors**: The company has issued $150 million in senior unsecured notes and has a $35 million revolving credit facility, requiring compliance with covenants. The substantial indebtedness could affect financial flexibility.

Next Steps

• File the definitive proxy statement for the 2026 annual meeting of stockholders within 120 days after the fiscal year end.
• The ceding fee to AmFam will increase to 3.25% on May 23, 2026, and to 5.0% on May 23, 2027.
• The Cyber quota share reinsurance treaty renews on January 1.
• The commercial auto quota share treaty within the Casualty division renews on March 1.
• The remainder of the reinsurance treaties renew on May 1.
• BICI may submit a written request for the Wisconsin OCI to consider whether the terms of the Wisconsin OCI Stipulation and Order should be continued or modified upon the earlier of a change in control or the fifth anniversary of its effective date (December 18, 2020).
• The company is currently evaluating the impact of ASU 2024-03 (Expense Disaggregation Disclosures) and ASU 2025-06 (Accounting for Internal-Use Software) on its financial statement disclosures.
• The company is evaluating the effects of ASU 2025-12 (Codification Improvements) on its consolidated financial statements.

Key Dates

Recommendation

The company demonstrates strong top-line growth in premiums and net income, driven by effective scaling and investment income. However, the deterioration in core underwriting profitability, evidenced by a higher loss ratio and combined ratio, and a decrease in underwriting income, is a significant concern. The planned increase in ceding fees to AmFam will further pressure future underwriting margins. While the company has a strong balance sheet and a modern operating model, the mixed financial performance and reliance on a few key brokers suggest a 'hold' recommendation. Investors should monitor the trend in underwriting profitability and the impact of increasing related-party fees.

Keywords

Specialty Insurance, Commercial P&C, Excess & Surplus Lines, Underwriting, Insurance Growth, Financial Performance, SEC Filing, 10-K, Casualty Insurance, Professional Liability, Healthcare Liability, Baleen Specialty, Reinsurance, Investment Income, Loss Ratio, Combined Ratio, Cybersecurity, AI in Insurance, AmFam Partnership, Public Company Costs, Debt Financing